MBX Biosciences Begins Phase 3 Trial for Chronic Hypoparathyroidism Treatment

MBX Biosciences, Inc. has initiated its pivotal Phase 3 oPTimize trial for once-weekly canvuparatide, with the first patient now dosed. This significant step in clinical development targets adults with chronic hypoparathyroidism, moving the potential therapy closer to commercialization. The announcement was made via an 8-K filing.